X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs WOCKHARDT LTD. - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA WOCKHARDT LTD. SUN PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 23.6 -15.2 - View Chart
P/BV x 3.4 2.5 138.0% View Chart
Dividend Yield % 0.7 1.3 50.5%  

Financials

 SUN PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
WOCKHARDT LTD.
Mar-17
SUN PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs8421,129 74.6%   
Low Rs572627 91.3%   
Sales per share (Unadj.) Rs131.6363.1 36.2%  
Earnings per share (Unadj.) Rs32.7-20.4 -159.9%  
Cash flow per share (Unadj.) Rs38.0-7.0 -544.4%  
Dividends per share (Unadj.) Rs3.5010.00 35.0%  
Dividend yield (eoy) %0.51.1 43.4%  
Book value per share (Unadj.) Rs152.7301.8 50.6%  
Shares outstanding (eoy) m2,399.26110.55 2,170.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x5.42.4 222.3%   
Avg P/E ratio x21.6-42.9 -50.4%  
P/CF ratio (eoy) x18.6-125.9 -14.8%  
Price / Book Value ratio x4.62.9 159.2%  
Dividend payout %10.7-48.9 -21.9%   
Avg Mkt Cap Rs m1,696,87797,063 1,748.2%   
No. of employees `00017.56.8 258.8%   
Total wages/salary Rs m49,0239,665 507.2%   
Avg. sales/employee Rs Th18,028.35,931.8 303.9%   
Avg. wages/employee Rs Th2,798.81,428.1 196.0%   
Avg. net profit/employee Rs Th4,479.5-334.0 -1,341.2%   
INCOME DATA
Net Sales Rs m315,78440,146 786.6%  
Other income Rs m6,2321,143 545.4%   
Total revenues Rs m322,01641,289 779.9%   
Gross profit Rs m100,893128 78,822.4%  
Depreciation Rs m12,6481,489 849.2%   
Interest Rs m3,9982,253 177.5%   
Profit before tax Rs m90,479-2,472 -3,660.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116-211 -5,739.3%   
Profit after tax Rs m78,462-2,260 -3,471.2%  
Gross profit margin %31.90.3 10,020.8%  
Effective tax rate %13.48.5 156.8%   
Net profit margin %24.8-5.6 -441.3%  
BALANCE SHEET DATA
Current assets Rs m329,53746,160 713.9%   
Current liabilities Rs m178,87019,258 928.8%   
Net working cap to sales %47.767.0 71.2%  
Current ratio x1.82.4 76.9%  
Inventory Days Days79101 78.4%  
Debtors Days Days8394 88.5%  
Net fixed assets Rs m204,76640,165 509.8%   
Share capital Rs m2,399553 434.1%   
"Free" reserves Rs m363,99732,814 1,109.3%   
Net worth Rs m366,39733,367 1,098.1%   
Long term debt Rs m14,36131,903 45.0%   
Total assets Rs m614,10289,687 684.7%  
Interest coverage x23.6-0.1 -24,329.8%   
Debt to equity ratio x01.0 4.1%  
Sales to assets ratio x0.50.4 114.9%   
Return on assets %13.40 -156,402.0%  
Return on equity %21.4-6.8 -316.1%  
Return on capital %24.8-0.3 -7,409.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,1189,121 483.7%   
Fx outflow Rs m24,4842,133 1,147.8%   
Net fx Rs m19,6346,988 281.0%   
CASH FLOW
From Operations Rs m70,822-2,695 -2,628.2%  
From Investments Rs m-42,216-6,863 615.2%  
From Financial Activity Rs m-22,85412,545 -182.2%  
Net Cashflow Rs m6,1073,010 202.9%  

Share Holding

Indian Promoters % 63.7 74.5 85.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 2.3 223.0%  
FIIs % 23.0 7.7 298.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 8.3 15.4 53.9%  
Shareholders   133,026 67,757 196.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  AJANTA PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS